Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
41 hedge funds and large institutions have $4.97M invested in Nymox Pharmaceutical Corp in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 12 closing their positions.
4% more call options, than puts
Call options by funds: $80K | Put options by funds: $77K
2.05% less ownership
Funds ownership: 7.11% → 5.06% (-2%)
9% less funds holding
Funds holding: 45 → 41 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
44% less capital invested
Capital invested by funds: $8.92M → $4.97M (-$3.96M)
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.02M |
| 2 |
Goldman Sachs
New York
|
+$174K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$138K |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$87K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.64M |
| 2 |
State Street
Boston,
Massachusetts
|
-$808K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$214K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$181K |
| 5 |
Bank of New York Mellon
New York
|
-$147K |
NYMX Hedge Fund Activity: Q2 2019 in Review
41 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2019, worth a combined $4.97M — down 44% from $8.92M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NYMX and 8 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.02M. The largest seller was BlackRock, cutting an estimated $2.64M.
- 41 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2019, down from 45 in Q1 2019.
- Funds reported $4.97M of Nymox Pharmaceutical Corp stock for Q2 2019, down 44% quarter-over-quarter.
- 8 funds opened new Nymox Pharmaceutical Corp positions in Q2 2019 and 12 closed out, a net change of -4 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2019 was Millennium Management, an estimated $2.02M added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2019 was BlackRock, an estimated $2.64M sold.
Based on aggregated 13F filings for Q2 2019.